AZN•benzinga•
AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients
Summary
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 14, 2025 by benzinga